Sign in
Active, not recruitingPhase 3

Low Dose Thrombolysis, Ultrasound Assisted Thrombolysis or Heparin for Intermediate High Risk Pulmonary Embolism

Key facts

Who runs it
Copenhagen University Hospital, Rigshospitalet
Where
Denmark4 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 3
People taking part
210 people, planned
Started
6 Jun 2019
Ended
30 Nov 2024
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Alteplase 20 Mg Powder for Solution for Injection Vial
  • Ultrasound assisted Thrombolysis
Record updated
15 November 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • Informed consent for trial participation
  • Intermediate high-risk PE according to ESC criteria
  • Thrombus visible in main, lobar or segmental pulmonary arteries on CT angiography
  • 14 days of symptoms or less

Who cannot take part

  • Ongoing oral anticoagulation therapy (heparins, aspirin, antiplatelet therapy and NOAC allowed)
  • Absolute contraindications for thrombolysis; Hemorrhagic stroke or stroke of unknown origin at any time; Ischemic stroke in the preceding 6 months; Central nervous system damage or neoplasms; Recent major trauma/surgery/head injury in the preceding 3 weeks; Gastrointestinal bleeding within the last month; Known bleeding risk
  • Altered mental state (GCS < 14)
  • No qualifying CT angiography performed (> 24 hour since CT angiography)
  • Females of child bearing potential, unless negative HCG test is present
  • Thrombolysis for PE within 14 days of randomization
  • Thrombus passing through patent Foramen Ovale (risk of paradoxical embolism)
  • Comorbidity making 6 months survival unlikely

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Open label clinical randomized trial comparing three strategies for managing acute intermediate-high risk pulmonary embolism

The 3 groups in the trial

  • USAT + low dose thrombolysisExisting treatment, for comparison

    UltraSound Assisted Thrombolysis (USAT) with low dose thrombolysis (20 mg of rtPA, Alteplase) over 6 hours plus unfractionated heparin (UFH) or low molecular weight heparin (LMWH) within 12 hours of randomization

    Treatment: Alteplase 20 Mg Powder for Solution for Injection Vial and Ultrasound assisted Thrombolysis

  • Low dose thrombolysisExisting treatment, for comparison

    Intravenous low dose thrombolysis (20 mg of rtPA, Alteplase) over 6 hours plus UFH or low molecular weight heparin (LMWH).

    Treatment: Alteplase 20 Mg Powder for Solution for Injection Vial

  • Heparin aloneNo study treatment, for comparison

    UFH or low molecular weight heparin (LMWH) only (with option for conventional thrombolysis according to local protocols for hemodynamic deterioration)

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Publications
Record updated
15 November 2024